Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 single ascending dose and multiple ascending dose study of LCA-0321
NL-OMON60640Phase 1Recruiting
- Sponsor
- Lycia Therapeutics
- Start
- Apr 2026
- Modality
- Lysosome-Targeting Antibody Chimeras (LYTAC / CataLYTAC) → Antibody-Based Degraders → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1 trial of LCA-0321 in Graves' disease (2 arms), sponsored by Lycia Therapeutics. Primary endpoint: Primary endpoint(s). Started Apr 2026; status: recruiting.
02
Drugs
LCA-0321
03
Conditions
Graves' disease
Beyond the preview
Go deeper on NL-OMON60640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60640.